Myricx

The challenge: Currently, over 90% of the clinical antibody–drug conjugate (ADC) pipeline is based on only three mechanisms. There is a need to diversify the ADC pipeline to offer more treatment options to people who respond poorly to well-known payloads.

The breakthrough: Myricx Bio’s cofounders identified a novel class of ADC payload based on N-myristoyltransferase (NMT) inhibitors to address the needs not met by existing payloads. Myricx has demonstrated the excellent preclinical efficacy and safety of its novel NMT inhibitors across multiple solid tumour-associated antigens and cancer cell types.

Our role: Cancer Research Horizons received equity in Myricx and is entitled to a share of future licensing revenues in exchange for licensing Cancer Research UK-funded IP. Separately, we participated in the company’s £90m Series A funding round in July 2024.